| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $90K | — |
| R&D Expense | $21.1M | -29.7% |
| SG&A Expense | $15.2M | +26.0% |
| Operating Income | -$36.2M | +13.9% |
| Net Income | -$33.9M | +11.4% |
| EPS (Basic) | -$1.09 | +14.2% |
| EPS (Diluted) | -$1.09 | +14.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $48.0M | -34.2% |
| Current Assets | $49.4M | -33.7% |
| Total Assets | $51.8M | -32.7% |
| Current Liabilities | $8.0M | -2.2% |
| Total Liabilities | $43.9M | -0.5% |
| Stockholders' Equity | $7.8M | -76.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$24.6M | +25.7% |
| Capital Expenditures | $104K | +845.5% |
| Investing Cash Flow | -$104K | -845.5% |
| Financing Cash Flow | -$217K | -100.7% |
| Free Cash Flow | -$24.7M | +25.4% |